10.1136/jitc-2022-005755
10.1136/jitc-2022-005755 · doi-reference
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
10.1200/jco.21.00612 · doi-reference
Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma
10.1158/1078-0432.ccr-17-2267 · doi-reference
Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
10.1158/1078-0432.ccr-21-4499 · doi-reference
Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma
10.1158/1078-0432.ccr-21-1171 · doi-reference
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1
10.1200/jco.2019.37.15_suppl.2518 · doi-reference
Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma
10.1200/jco.2016.66.7220 · doi-reference
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies
10.1158/1078-0432.ccr-13-0380 · doi-reference
Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma
10.1097/cji.0b013e31826e8f5f · doi-reference
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
10.1158/1078-0432.ccr-11-0116 · doi-reference
Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens
10.1200/jco.2008.16.5449 · doi-reference
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
10.1200/jco.2005.00.240 · doi-reference
A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma
10.1097/00002371-200205000-00007 · doi-reference
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2
10.1093/jnci/86.15.1159 · doi-reference
Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer
10.1016/s0140-6736(89)91609-7 · doi-reference
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
10.1084/jem.20050732 · doi-reference
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report [see comments]
10.1056/nejm198812223192527 · doi-reference
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma
10.4049/jimmunol.138.3.989 · doi-reference
Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
10.1097/ppo.0000000000000608 · doi-reference
Metastasectomy for Tumor-Infiltrating Lymphocytes: An Emerging Operative Indication in Surgical Oncology
10.1245/s10434-017-6266-8 · doi-reference
KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
10.1136/jitc-2020-001806 · doi-reference
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
10.1016/s1470-2045(22)00687-8 · doi-reference
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(20)30934-x · doi-reference
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
10.3390/cancers15051629 · doi-reference
Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens
10.1186/s12967-023-04172-w · doi-reference
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors
10.1016/j.medj.2022.12.007 · doi-reference
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
10.1038/s41591-021-01623-z · doi-reference
Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1–based immunotherapy
10.1158/1078-0432.ccr-18-2795 · doi-reference
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy
10.1158/1078-0432.ccr-21-1283 · doi-reference
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
10.1038/s41591-020-01211-7 · doi-reference
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
10.1172/jci91190 · doi-reference
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice
10.18632/oncotarget.5950 · doi-reference
Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis
10.1158/1078-0432.ccr-20-0458 · doi-reference
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
10.1126/science.aad0095 · doi-reference
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
10.1056/nejmoa1406498 · doi-reference
Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma
10.1200/jco.2022.40.16_suppl.9501 · doi-reference
Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events
10.1136/jitc-2021-002435 · doi-reference
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
10.1056/nejmoa2211437 · doi-reference
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
10.1016/s1470-2045(19)30151-2 · doi-reference
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
10.1038/s41591-018-0198-0 · doi-reference
